Welcome to our dedicated page for Odyssey Health news (Ticker: ODYY), a resource for investors and traders seeking the latest updates and insights on Odyssey Health stock.
Odyssey Health, Inc. reports developments tied to its medical technology portfolio, commercial agreements and capital structure. The company focuses on life-saving and life-enhancing medical solutions through acquired or developed assets, intellectual property and technologies. Recent company updates include exclusive worldwide marketing and distribution rights for BreastCheck™ through Odyssey Medical Devices, development work on the patented Save A Life choking rescue device, and commercial service arrangements intended to add recurring revenue.
Odyssey Health news also includes financing facilities, promissory-note activity, operating and financial results, shareholder voting matters, and completed portfolio transactions such as the sale of its neurological drug-therapy assets related to concussion, Niemann Pick Disease Type C, powder formulation technology and a nasal delivery device.
Odyssey Group International, Inc. (OTCQB:ODYY) has completed its acquisition of PRV-002, a novel neurosteroid aimed at treating concussions, from Prevacus, Inc. This all-stock transaction positions Odyssey to address a significant market opportunity, as over 3 million concussions occur annually in the U.S., with no FDA-approved drug currently available. PRV-002 has shown promise in preclinical studies, demonstrating effective brain biodistribution and positive behavioral outcomes. The company anticipates launching Phase 1 clinical trials in Q2 2021, with Dr. Jake VanLandingham leading the drug development efforts.
Odyssey Group International, Inc. (OTCQB:ODYY) has announced the successful completion of the design development phase of its Save A Life choking rescue device, in collaboration with Tanaka Kapec Design Group. The product is now transitioning to the prototyping stage, where experts will test and refine its effectiveness. The collaboration has optimized the device's design for enhanced ergonomics and usability. CEO Michael Redmond expressed enthusiasm for advancing towards FDA submission to improve outcomes for choking emergencies.
Odyssey Group International, Inc. (OTCQB:ODYY) and Prevacus Inc. announced positive pre-clinical results for PRV-002, a nasal drug aimed at treating concussions. The studies indicated that PRV-002 demonstrated rapid brain absorption, with enhanced bioavailability when formulated as nanoparticles. After nasal administration, approximately 40% more of the drug was detected in brain tissues after 8 hours compared to its native form. Odyssey is set to finalize its acquisition of PRV-002 by the end of February, contingent on shareholder approval.
Odyssey Group International, Inc. (OTCQB: ODYY) announced significant media coverage for its concussion treatment, Prevasol. Recent appearances include CheddarTV on February 5, Newsmax on February 7, and Fox Business on February 8, featuring CEO Dr. Jake VanLandingham and former NFL stars discussing brain injuries. The company is excited about its pending partnership with Prevacus, with a definitive agreement to acquire the drug candidate PRV-002 expected to close by the end of February 2021, pending shareholder approval.
Odyssey Group International, Inc. (OTCQB: ODYY) has announced significant advancements in its product development for the fiscal year ending July 31, 2020. Key highlights include the continued development of the Save a Life® choking rescue device and the initiation of the CardioMap® device aimed at heart disease diagnostics. The company appointed Mike Contarino to lead product development and established a partnership with Majic LLC for manufacturing quality assurance. Financial backing is secured from Lincoln Park Capital as Odyssey prepares for FDA submissions and plans international distribution.